InvestLog
SPRY ARS Pharmaceuticals, Inc. logo

SPRY ARS Pharmaceuticals, Inc.

Healthcare
$8.17+0.00%OpenMarket Cap: $811.3M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

12.86

P/S

7.97

EV/EBITDA

-4.43

DCF Value

$-4.66

FCF Yield

-22.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

77.1%

Operating Margin

-204.5%

Net Margin

-200.0%

ROE

-153.6%

ROA

-68.8%

ROIC

-84.8%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$22.7M$-60.6M$—
Q4 null$28.1M$-41.3M$—
FY null$84.3M$-171.3M$—
Q3 null$32.5M$-51.2M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$25.50

Target (Median)

$25.50

Target Range

$25.00 - $26.00

0 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
Tanimoto Sarina10 percent owner, officer: CHIEF MEDICAL OFFICER
SellMon Jan 05
Tanimoto Sarina10 percent owner, officer: CHIEF MEDICAL OFFICER
SellMon Jan 05
Scott Kathleen D.officer: Chief Financial Officer
SellMon Jan 05
Lowenthal Richard Edirector, 10 percent owner, officer: PRESIDENT AND CEO
SellMon Jan 05
Lowenthal Richard Edirector, 10 percent owner, officer: PRESIDENT AND CEO
SellMon Jan 05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

0.80

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Peers

ABUS logoABUSGHRS logoGHRSKURA logoKURALENZ logoLENZNBTX logoNBTXPROK logoPROKPVLA logoPVLARZLT logoRZLTSVRA logoSVRATYRA logoTYRA